The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Vesomni 6 mg/0.4 mg modified-release tablets

Astellas Pharma Co. LimitedPA1241/016/001

Main Information

Trade NameVesomni 6 mg/0.4 mg modified-release tablets
Active SubstancesSolifenacin succinate
Tamsulosin hydrochloride
Dosage FormModified-release tablet
Licence HolderAstellas Pharma Co. Limited
Licence NumberPA1241/016/001

Group Information

ATC CodeG04CA53 tamsulosin and solifenacin


License statusAuthorised
Licence Issued06/01/2014
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0101-154-021
Interchangeable List DocumentPDF of Interchangeable List
« Back